Latest Headlines

  1. BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements With Fidelion Diagnostics For Southeast Asia MRD Commercialization 11/12/2025

    BioNexus Gene Lab Corp. (“BGLC,” Nasdaq: BGLC) today announced it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and Tongshu Biotechnology (Hong Kong) Co., Limited (“Tongshu”), among other parties, to commercialize VitaGuard™, a high-fidelity, tumor-naïve liquid-biopsy platform for minimal residual disease (MRD).

  2. GenomOncology Partners With Glioblastoma Foundation To Accelerate Precision Glioblastoma Brain Cancer Treatment 11/11/2025

    GenomOncology today announced a strategic partnership with the Glioblastoma Foundation to transform genomic testing for the nation's most aggressive brain cancer, glioblastoma.

  3. Shimadzu Introduces i-Series LC-2070/LC-2080 Integrated HPLC Systems 11/10/2025

    Shimadzu Scientific Instruments announces the launch of the i-Series LC-2070/LC-2080 Integrated High-Performance Liquid Chromatographs (HPLC), the latest evolution of its i-Series line.

  4. Guardant Health Expands Tissue-Free Reveal Test To Include Late-Stage Therapy Response Monitoring 11/10/2025

    Guardant Health, Inc. a leading precision oncology company, today announced the expansion of its Guardant Reveal blood test to include late-stage therapy response monitoring for patients with solid tumors.

  5. Geneseeq Receives NMPA Approval For PanTRKare™ - China's First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit For NTRK Gene Fusions 11/10/2025

    Geneseeq Technology Inc., a global precision oncology company, today announced its PanTRKare™NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit has received marketing authorization from China's National Medical Products Administration (NMPA).

  6. Optimizing Sample Traceability: Speed And Precision Via Laser Marking Technology 11/7/2025

    Earlier this year, AFYS3G announced the launch of the Information Marking System Lambda768. A next-generation laser marking solution engineered to redefine efficiency in sample identification.

  7. Exact Sciences Announces Breakthrough Results From Landmark Study Demonstrating Superior Early Detection Of Liver Cancer With Blood-Based Surveillance Test 11/7/2025

    Exact Sciences Corp a leading provider of cancer screening and diagnostic tests, today announced pivotal clinical validation results from the ALTUS study (NCT: 05064553).

  8. YD Bio And EG BioMed Expand U.S. Access To OkaiDx™, A cfDNA Methylation Blood Test For Post Treatment Breast Cancer Monitoring 11/5/2025

    YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc.

  9. Illumina And Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights 11/5/2025

    Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, today emerged from stealth with $6.7M in seed funding led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures, Alumni Ventures, and AME Cloud Ventures.

  10. QIAGEN To Acquire Parse Biosciences, Expanding Its Sample Technologies Portfolio Into Highly Scalable Single-Cell Solutions 11/4/2025

    QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.